Background. Acute kidney injury (AKI) is a serious complication following lung transplantation (LTx). We aimed to describe the incidence and outcomes associated with AKI following LTx. Methods. A retrospective population-based cohort study of all adult recipients of LTx at the University of Alberta between 1990 and 2011. The primary outcome was AKI, defined and classified according to the Kidney Disease: Improving Global Outcomes (KDIGO) criteria, in the first 7 post-operative days. Secondary outcomes included risk factors, utilization of renal replacement therapy (RRT), occurrence of post-operative complications, mortality and kidney recovery. Results. Of 445 LTx recipients included, AKI occurred in 306 (68.8%), with severity classified as Stage I in 38.9% (n = 173), Stage II in 17.5% (n = 78) and Stage III in 12.4% (n = 55). RRT was received by 36 (8.1%). Factors associated with AKI included longer duration of cardiopulmonary bypass [ per minute, odds ratio (OR) 1.003; 95% confidence interval (CI), 1.001-1.006; P = 0.02], and mechanical ventilation [ per hour (log-transformed), OR 5.30; 95% CI, 3.04-9.24; P < 0.001], and use of cyclosporine (OR 2.03; 95% CI, 1.13-3.64; P = 0.02). In-hospital and 1-year mortality were significantly higher in those with AKI compared with no AKI (7.2 versus 0%; adjusted P = 0.001; 14.4 versus 5.0%; adjusted P = 0.02, respectively). At 3 months, those with AKI had greater sustained loss of kidney function compared with no AKI [estimated glomerular filtration rate, mean (SD): 68.9 (25.7) versus 75.3 (22.1) mL/min/1.73 m
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I N T RO D U C T I O N
Lung transplantation (LTx) has emerged as the preferred treatment modality for patients with a variety of end-stage lung diseases to prolong life expectancy and improve quality of life [1] . Despite significant improvements in both short-and longterm mortality [2] , medical complications after transplantation contribute to significant morbidity and mortality [3] .
Acute kidney injury (AKI) is a serious complication after LTx, occurring in 39-65% of patients [4] [5] [6] [7] [8] [9] in which 5-13% require renal replacement therapy (RRT) [10, 11] . Post-operative AKI has been associated with reduced patient and graft survival [2, 5, 6] . In addition, the declines in kidney function and new chronic kidney disease (CKD) are increasingly recognized as important sources of long-term morbidity after LTx [12] [13] [14] .
Prior studies addressing AKI after LTx have been limited for reasons including use of historical [4, 5, 7] and non-validated definitions of AKI [8, 9] small sample size [4, 5, [7] [8] [9] , single center [4] [5] [6] [7] [8] [9] 11 ] inclusion of only RRT treated patients [10, 11] and inadequate adjustment for available confounding variables [6] . These data have focused largely on pre-operative susceptibilities associated with AKI after LTx, including age, kidney function, etiology of lung disease, presence of pulmonary hypertension and diabetes mellitus [6] . Few studies have examined for peri-operative risk factors [7] .
We hypothesized that post-operative AKI following LTx would be common and associated with worse outcome. Specifically, we aimed to describe the incidence and severity of postoperative AKI in a large cohort of LTx recipients; to characterize the risk factors and to evaluate its impact on post-operative complications, mortality and kidney function.
M AT E R I A L S A N D M E T H O D S
This study followed the strengthening the reporting of observational studies in epidemiology (STROBE) statement for observational studies [15] (Supplementary data, File). The Health Research Ethics Board at the University of Alberta approved this study prior to commencement (HREB File # Pro00025935). The requirement for individual informed consent was waived.
Study design, setting and participants
We performed a retrospective population-based cohort study of all adult patients receiving LTx at the University of Alberta between 1990 and 2011. The LTx program at the University of Alberta, started in 1986, is currently the second largest in Canada [16] , averaging 33 transplants per year, and is the referral center for all LTx in the Provinces of Alberta and Saskatchewan ( population base ∼3.8 million).
The inclusion criteria were (i) adult (age ≥18 years); (ii) received LTx (any of single, double or heart-lung transplant).
The exclusion criteria were (i) death <24 h of LTx (one patient); (ii) pre-operative CKD ≥Stage 4, defined by the Kidney Disease: Improving Global Outcomes (KDIGO) classification [17] (one patient); (iii) pre-operative AKI or receipt of RRT within 1 month of prior to LTx and (iv) no data available on vital status.
Surgical technique
Cardiopulmonary bypass (CPB) was used in the majority of cases (76%) with trends varying over time. Standardized post-operative care was provided to all patients with hemodynamic monitoring performed in a specialized cardiovascular surgical intensive care unit (ICU).
Immunosuppression and antibiotic protocol
All patients received induction therapy consisting of corticosteroids (intravenous methylprednisolone 500 mg administered intra-operatively before reperfusion of the allograft followed by tapering methylprednisolone or prednisone), antilymphocyte therapy [antithymocyte globulin (ATGAM) 10 mg/kg/day for 5-10 days in 308 patients, rabbit antithymocyte globulin (Thymoglobulin) 1.5 mg/kg/day for 5-10 days in 11 patients or dacluzimab 1 mg/kg on Days 1 and 4 in 83 patients] and azathioprine 100 mg/day or mycophenolate mofetil 3 g/day. In 2000, mycophenolate mofetil replaced azathioprine in the baseline regimen for all patients. Calcineurin inhibitors were introduced on Days 2-5 using either tacrolimus (TAC) (target trough 10-15 ng/mL) or cyclosporine (CYA) (target trough 250-350 ng/mL) prior to the introduction of TAC. While CYA was predominantly used until 2006, TAC was most commonly used thereafter. The standard perioperative antimicrobial regimen consisted of prophylactic cefazolin (3 doses) or vancomycin (2 doses) if there was a penicillin allergy; sulfamethoxazole 400 mg/trimethoprim 80 mg daily; fluconazole daily and ganciclovir if either recipient or donor cytomegalovirus serology was positive. This regimen was individualized according to peri-operative tissue cultures.
Variables
The primary outcome was occurrence of AKI in the first 7 post-operative days. Secondary outcomes included ICU, inhospital, 1-year and 5-year mortality, utilization and duration of RRT; ICU and hospital lengths of stay; ICU readmission; duration of mechanical ventilation (MV); incidence of re-intubation; incidence of post-operative tracheostomy; kidney recovery and function at 3 months after LTx.
Operational definitions
Lung allocation score (LAS) value [18] was used as a surrogate for pre-operative illness severity. The LAS was retrospectively calculated for all patients. Infection was defined as an inflammatory response presumably due to microorganisms isolated on tissue cultures. Bronchial dehiscence was defined as discontinuity of bronchial anastomosis diagnosis by bronchoscopy. AKI was classified and severity was staged according to the serum creatinine (sCr) criteria of the KDIGO classification scheme [19] . We defined the presence of AKI by an absolute increase in sCr ≥26.5 µmol/L or 1.5-fold relative change from baseline sCr in the first 7 post-operative days. Severity was classified as Stage I: increase in sCr ≥26.5 µmol/L or 1.5-1.9 times baseline; Stage II: increase in sCr 2.0-2.9 times baseline; Stage III: increase in sCr 3.0 times baseline or increase in sCr ≥353.6 µmol/L or RRT initiation. Urine output data were unavailable. Baseline sCr was defined as the lowest sCr value available prior to the date of transplantation. Baseline estimated glomerular filtration rate (eGFR) was calculated according to the Chronic Kidney Disease Epidemiology Collaboration formula [20] . The presence of CKD was defined by an eGFR < 60 mL/min/1.73 m 2 [17] .
Data sources
Data were obtained by access to the University of Alberta LTx database and medical record review. All patients undergoing LTx or combined heart and LTx have been prospectively entered into the database since 1997. The database routinely captures demographic (i.e. age, sex, weight), pre-operative (i.e. pulmonary diagnosis, pulmonary function, co-morbid disease), intra-operative (i.e. procedure type, donor/recipient data) and post-operative (i.e. acute physiology, organ function, adverse events, immunosuppression, survival, graft function) data on standardized case report forms. Patients' medical records were reviewed for Supplementary data not captured by the LTx database (i.e. characteristics of RRT, kidney function).
Statistical analysis
Descriptive statistics were calculated and expressed as mean [±standard deviation (SD)] or median [intraquartile range (IQR)] for parametric and non-parametric continuous variables and count (%) for categorical variables, respectively. We compared variables between individuals with and without AKI and among different stages of AKI and no AKI by using Student's t-test, Mann-Whitney U test or Fisher's exact test where appropriate. In the event of missing data values or loss to follow-up, data were not replaced or estimated. Multivariate logistic regression was used to calculate the adjusted odds ratio (OR) with 95% confidence intervals (CI) for the variables associated with AKI and for the association between AKI and mortality. In addition to variables associated with each outcome on exploratory univariate analysis with a level of significance P < 0.2, those with biological plausibility were incorporated in the multivariate model. We assessed for collinearity. Model fit was assessed by the Hosmer-Lemeshow goodness-of-fit test and discrimination by the area under the receiver operative characteristic curve. Survival at 1-and 5 years was estimated using the Kaplan-Meier method stratified by AKI and compared using the log-rank test. A P < 0.05 was considered statistically significant for all comparisons. Statistical analysis was performed using SPSS version 21.0 (IBM Corp, Armonk, NY).
R E S U LT S
Of 484 patients receiving LTx during the study period, 445 patients fulfilled eligibility (Figure 1 ). The median (IQR) age was 54 years (41-60), 38% were female and the most common etiologies of lung disease were chronic obstructive pulmonary disease (COPD; 34%, n = 149), idiopathic pulmonary fibrosis (IPF; 22%, n = 99) and cystic fibrosis (16%, n = 71). Most patients received sequential double LTx (79.6%; n = 364) with fewer receiving single LTx (16%, n = 71) or heart-lung transplant (4.4%; n = 20). The median (IQR) duration of follow-up was 3.9 years (1.5-7.1).
Incidence of AKI AKI occurred in 68.8% of patients (n = 306) in the 7 days following LTx [median (IQR): 1 (1-2) day] (Supplementary data, Figure S1 ). AKI Stage I occurred in 38.9% (n = 173); Stage II in 17.5% (n = 78) and Stage III in 12.4% (n = 55) of patients. Figure S2 ). This was most notable for more severe stages of AKI (AKI Stage I: 37.5 versus 47.0%, P = 0.14; AKI Stage II: 19.3 versus 7.6%; P = 0.02; AKI Stage III: 14.0 versus 3.0%; P = 0.01).
Risk factors for AKI
In the univariate analysis, higher LAS score (OR 1.05; 95% CI, 1.02-1.08; P = 0.003) and duration of CPB ( per minute OR 1.003; 95% CI, 1.001-1.005; P < 0.001) were the only factors significantly associated with post-operative AKI (Tables 1 and 2 ). In adjusted analysis, longer CPB time [ per min, adjusted (adj) OR 1.003; 95% CI, 1.001-1.006; P = 0.02), longer duration MV ( per natural log hour, adj-OR 5.30; 95% CI, 3.04-9.24; P < 0.001) and CYA use (adj-OR 2.03; 95% CI, 1.13-3.64; P = 0.02) were independently associated with postoperative AKI (Table 3) .
Short-and long-term survival
Crude in-hospital, 1-year and 5-year survival after LTx were 95.2, 88.5 and 59.9%, respectively. The ICU and in-hospital mortality were both higher for the AKI group compared with no-AKI (3.9 versus 0%, P = 0.02; 7.2 versus 0%, P = 0.001, respectively) and we observed a gradient increase in the risk of death with worsening AKI severity (Figure 2 and Supplementary data, Figure S3 ). Infection (18.2%) and bronchial dehiscence (18.2%) were more common among AKI patients and portended a higher risk of death in AKI compared with non-AKI (10.5 versus 4.3%, P = 0.04; 3.3 versus 0%, P = 0.04). At 1 year, AKI was independently associated with higher mortality (adj-OR 2.8, 95% CI, 1.2-6.8; P = 0.02) ( Table 4) . Figure S4 ). The re-intubation rate (28.9 versus 17.1%; OR 3.6; 95% CI, 1.3-9.5, P = 0.01) and use of post-operative tracheostomy (27.5 versus 9.4%; OR 3.9; 95% CI, 1.6-9.3, P = 0.002) were significantly higher for AKI compared with non-AKI patients and also showed a gradient increase with AKI severity (Supplementary data, Figure S5 ). There was no
Secondary outcomes and complications
difference in ICU readmission rate between groups (3.6 versus 3.6%, P = 1.0).
Kidney recovery
At ICU discharge, 14 patients (47% of surviving patients who received RRT) remained RRT dependent, while among survivors at hospital discharge, only 8 (22%) were RRT dependent. At 3 months after LTx, eGFR (mean SD) was significantly lower in those with AKI compared with no AKI [68.9 (25.7) versus 75.3 (22.1) mL/min/1.73 m 2 , P = 0.01; n = 422).
There was a gradient decrease in eGFR with greater AKI severity; however, all groups had significant declines in kidney function post-operatively ( Figure 3 ).
D I S C U S S I O N
We performed a retrospective population-based cohort study of all patients receiving LTx from a large Canadian region to 
O R I G I N A L A R T I C L E
A K I f o l l o w i n g o r t h o t o p i c l u n g t r a n s p l a n t describe the incidence, severity, risk factors and outcomes associated with AKI.
Key findings
We found two-thirds of patients receiving LTx developed post-operative AKI, with 1 in 10 receiving RRT. The most important identifiable risk factors for AKI were duration of CPB, duration of MV and exposure to CYA. We also showed, in those developing post-operative AKI, a longer duration of ventilation, higher risk for re-intubation and tracheostomy, and longer stays in both ICU and hospital. Finally, we found AKI patients had a higher independent risk for death at 1 year, and among survivors, greater loss of kidney function at 3 months post-operatively.
Comparison with previous studies and interpretation of results In our study, the incidence of AKI after LTx (68.8%) was higher than previously reported [4, 5, 7] but similar to that recently described by Wehbe et al. [6] . Differences in the observed incidence between studies are likely attributable to differences in AKI definitions, duration of ascertainment of AKI and population case mix. Compared with prior investigations, we used the most recent consensus definition for AKI and ascertained AKI in the first post-operative week, based on data in cardiac surgery suggesting the worst AKI stage most commonly occurs within 48 h of surgery [21] and AKI developing within this timeframe would most likely be temporally associated with the procedure. The utilization of RRT following LTx in our study (8.1% ) is within the range previously reported (5.5-13.2%) [10, 22] . However, our data suggest the incidence of AKI has increased, showing a higher incidence in the most recent decade. We believe this is attributable to temporal changes in patient demographics, higher burden of comorbid disease, higher illness severity and an increased complexity of more recent LTx recipients (Supplementary data, e- Table 1) .
CPB is known to contribute to AKI after cardiac surgery [23, 24] and following LTx [11] . Our data not only confirm these findings, but also indirectly show 'dose-dependent' risk of AKI with exposure and/or longer durations of CPB (i.e. risk lower among single versus double LTx). The pathologic mechanisms linking CPB and AKI are multi-factorial and likely involve kidney hypoperfusion, loss of pulsatile flow, generation of microemboli, activation of systemic inflammatory mediators and direct nephrotoxicity (i.e. circulating free ironinduced toxicity) [25] .
Similar to Rocha et al. [4] , we found AKI was associated with prolonged post-operative MV. We extend these findings but also suggesting that post-operative AKI is associated with an increased risk for re-intubation and post-operative tracheostomy after LTx. There are numerous biologically plausible explanations for this association. First, lung injury (i.e. ischemic reperfusion) can incite distant organ inflammatory injury, including AKI [26, 27] . Secondly, MV itself can incite numerous changes that may negatively impact kidney function including (i) increased renal venous pressure (i.e. increased intrathoracic pressure, (ii) increased neuro-hormonal activation in response to increased intrathoracic pressure and positive end-expiratory pressure (i.e. non-osmotic release of arginine vasopressin) and (iii) by contributing to ventilatorinduced lung injury. Similarly, AKI itself may contribute to weaning failure and greater lung injury (i.e. alterations in alveolar permeability, aquaporin expression from non-osmotic release of arginine vasopressin and loss of fluid and acid-base homeostasis [28] ).
Calcineurin inhibitors are known to contribute to CKD after LTx [12, 29, 30] . We found that CYA was independently associated with post-operative AKI. This has been similarly shown in early CYA exposure in kidney transplant recipients [31] . However, the relationship between high exposure and decline in kidney function has recently been challenged in non-kidney transplant literature [32, 33] being attributable instead of to inter-individual variability and local kidney factors [34] . Finally, we could not find a clear protective effect of TAC over CYA on risk of early post-operative AKI, despite data supporting a benefit over CYA for kidney preservation in non-kidney solid organ transplantation [35, 36] including LTx [37] .
We did not find that baseline kidney function was an independent predictor of post-operative AKI in our study. This is in line with prior studies on AKI following LTx showing only an association with the development of chronic kidney dysfunction after LTx [4, 5, 12, 22] and contrasting the results reporting an association with increased risk of post-operative AKI [6] . This difference may relate to the relatively low prevalence of CKD in our cohort (i.e. patients with advanced CKD deemed unsuitable for LTx), the use of a different formula to define baseline eGFR, which may be more accurate to describe the association between lower eGFR, and adverse outcomes [17, 38] or the higher threshold we used to diagnose pre-operative CKD compared with Wehbe et al. [6] . However, we did find those achieving AKI Stage III had greater likelihood of CKD, similar to that described by George et al. [10] . While we did not shown any association between diabetes mellitus or pulmonary hypertension and AKI as previously reported [6] , the prevalence of these conditions in our cohort was also relatively low. In addition, our multivariable analysis integrated a number of additional intra-operative variables not assessed in prior studies that may account for these differences.
Survival at 1-and 5-years of 88.5 and 59.9%, respectively, compares favorably with the published data International Society of Heart and Lung Transplantation (ISHLT) registry data on LTx [2] and other works [4, 7] . Our data also confirm that post-operative AKI has an important modifying influence on long-term patient and graft survival following LTx [5] [6] [7] . While the ISHLT registry only shows the association between dialysis-dependent AKI and risk of death at 1 year [2] , we show that any early post-operative AKI was independently associated with increased long-term mortality risk. This finding further corroborates and extends the findings of Wehbe et al. [6] .
There were a significantly higher percentage of AKI patients dying from infection and bronchial dehiscence compared with non-AKI patients. The bidirectional interaction of AKI and sepsis has been previously described [39, 40] and probably results from immune dysfunction induced by AKI as well as from the resulting positive fluid balance associated organ dysfunction. The mechanism linking AKI and surgical complications, such as bronchial dehiscence, could plausibly be related to longer durations of positive pressure ventilation [41] associated with AKI and fluid accumulation.
Study limitations
Our study has several limitations that warrant consideration. Since our study is single center, and retrospective, it is potentially predisposed to bias and residual confounding. Secondly, our cohort includes patients from a period of over 20 years from a large Canadian region, where some differences and variation in selection criteria for LTx and immunosuppressive regimens occurred. This may limit the generalizability of our findings to other jurisdictions. Thirdly, we did not include the urine output criteria in our definition of AKI or fluid balance data in our analysis because these data were not available. Fluid overload has been consistently reported as an independent risk factor for worse outcomes in critically ill patients on MV [42] and particularly AKI patients [43, 44] . The impact of fluid balance following LTx and the modifying impact of AKI on duration of MV and mortality warrant further investigation, in particular, considering these patients have had ligation of their pulmonary lymphatics and that active diuresis is often initiated early in the post-operative period to reduce pulmonary edema and conserve graft function [5] . Finally, while we recognize that the retrospective calculation of LAS is potentially subject to bias, it represents a validated tool for the assessment of illness severity among LTx recipients.
CO N C L U S I O N S
AKI is common and increasingly encountered after LTx. Postoperative AKI is associated with a more complicated course and utilization of greater resources, including longer duration of ventilation, higher rates of re-intubation and tracheostomy and longer durations of ICU and hospital stay. Importantly, AKI was associated with higher mortality and worsened downstream kidney function.
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